426 related articles for article (PubMed ID: 30312438)
1. Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease.
Torres VE
Nephrol Dial Transplant; 2019 Jan; 34(1):30-34. PubMed ID: 30312438
[TBL] [Abstract][Full Text] [Related]
2. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.
Chebib FT; Perrone RD; Chapman AB; Dahl NK; Harris PC; Mrug M; Mustafa RA; Rastogi A; Watnick T; Yu ASL; Torres VE
J Am Soc Nephrol; 2018 Oct; 29(10):2458-2470. PubMed ID: 30228150
[TBL] [Abstract][Full Text] [Related]
3. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
Bennett H; McEwan P; Hamilton K; O'Reilly K
BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
[TBL] [Abstract][Full Text] [Related]
4. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
Torres VE; Higashihara E; Devuyst O; Chapman AB; Gansevoort RT; Grantham JJ; Perrone RD; Ouyang J; Blais JD; Czerwiec FS;
Clin J Am Soc Nephrol; 2016 May; 11(5):803-811. PubMed ID: 26912543
[TBL] [Abstract][Full Text] [Related]
5. Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.
Kramers BJ; van Gastel MDA; Boertien WE; Meijer E; Gansevoort RT
Am J Kidney Dis; 2019 Mar; 73(3):354-362. PubMed ID: 30578153
[TBL] [Abstract][Full Text] [Related]
6. [Tolvaptan, a vasopressin V
Yamada Y; Fujiki H; Mizuguchi H; Takeshita Y; Hattori K; Ohmoto K; Aihara M; Nagano K; Isakari Y; Yamamoto M; Yamamura Y
Nihon Yakurigaku Zasshi; 2022; 157(4):254-260. PubMed ID: 35781456
[TBL] [Abstract][Full Text] [Related]
7. A
Shoaf SE; Ouyang J; Sergeyeva O; Estilo A; Li H; Leung D
Clin J Am Soc Nephrol; 2020 May; 15(5):643-650. PubMed ID: 32241780
[TBL] [Abstract][Full Text] [Related]
8. An update on tolvaptan for autosomal dominant polycystic kidney disease.
Poch E; Rodas L; Blasco M; Molina A; Quintana L
Drugs Today (Barc); 2018 Sep; 54(9):519-533. PubMed ID: 30303493
[TBL] [Abstract][Full Text] [Related]
9. Review of tolvaptan for autosomal dominant polycystic kidney disease.
Baur BP; Meaney CJ
Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.
Edwards ME; Chebib FT; Irazabal MV; Ofstie TG; Bungum LA; Metzger AJ; Senum SR; Hogan MC; El-Zoghby ZM; Kline TL; Harris PC; Czerwiec FS; Torres VE
Clin J Am Soc Nephrol; 2018 Aug; 13(8):1153-1161. PubMed ID: 30026287
[TBL] [Abstract][Full Text] [Related]
11. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
[TBL] [Abstract][Full Text] [Related]
13. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
Gansevoort RT; van Gastel MDA; Chapman AB; Blais JD; Czerwiec FS; Higashihara E; Lee J; Ouyang J; Perrone RD; Stade K; Torres VE; Devuyst O;
Kidney Int; 2019 Jul; 96(1):159-169. PubMed ID: 30898339
[TBL] [Abstract][Full Text] [Related]
14. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
Chebib FT; Torres VE
Am J Kidney Dis; 2021 Aug; 78(2):282-292. PubMed ID: 33705818
[TBL] [Abstract][Full Text] [Related]
15. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
Oguro M; Kogure Y; Hoshino J; Ubara Y; Mizuno H; Sekine A; Kawada M; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Takaichi K
J Nephrol; 2018 Dec; 31(6):961-966. PubMed ID: 30357715
[TBL] [Abstract][Full Text] [Related]
16. Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan.
Muto S; Okada T; Shibasaki Y; Ibuki T; Horie S
Clin Exp Nephrol; 2021 Sep; 25(9):1003-1010. PubMed ID: 34089122
[TBL] [Abstract][Full Text] [Related]
17. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
Janssens P; Weydert C; De Rechter S; Wissing KM; Liebau MC; Mekahli D
Pediatr Nephrol; 2018 Mar; 33(3):395-408. PubMed ID: 28455745
[TBL] [Abstract][Full Text] [Related]
18. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
Blair HA; Keating GM
Drugs; 2015 Oct; 75(15):1797-806. PubMed ID: 26407729
[TBL] [Abstract][Full Text] [Related]
19. Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial.
Schaefer F; Mekahli D; Emma F; Gilbert RD; Bockenhauer D; Cadnapaphornchai MA; Shi L; Dandurand A; Sikes K; Shoaf SE
Eur J Pediatr; 2019 Jul; 178(7):1013-1021. PubMed ID: 31053954
[TBL] [Abstract][Full Text] [Related]
20. [ADPKD treatment: Tolvaptan and Octreotide].
Galliani M; Chicca S; Vitaliano E; Moscaritolo E; Calvaruso L; Iorio F; Paone A
G Ital Nefrol; 2019 Dec; 36(6):. PubMed ID: 31830392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]